


# Adrenal


[END0024](#)  
[Phase Ib Open-Label Study of Relacorilant in Combo w/ Pembrolizumab for in Adrenocortical Carcinoma with Excess Glucocorticoid Production](#)

PI: Kebebew  
Sponsor: Corcept Therapeutics Incorporated

### KEY


 Pending

 Open for Enrollment

 Observational Study

 Optional Path

 Trial Posting

 Enrollment on Hold

 Extension Study

 Immunotherapy